Sanofi and Regeneron’s blockbuster-to-be Dupixent made its Tuesday debut wearing a $37,000 list price. Ahead of approval, Regeneron CEO Len Schleifer said the partners were working with payers on a cost that would make the treatment for moderate-to-severe eczema readily available to patients. How do those two facts square up? Pretty well, according to analysts, number-crunchers and at least one payer that will foot the bill. And that’s a good thing for the launch. “Payer commentary since the approval has been largely positive,” said Leerink Partners analyst Geoffrey Porges. That, in turn, “suggests that patients may not be subject to the exhaustive prior authorization and step edit requirements that have delayed and limited access to innovative medicines in recent years.” This time could be different, partly because of that up-front work with payers and pricing arbiters. The Institute for Clinical and Economic Research, the relatively new, self-appointed cost-effectiveness watchdog, was in touch with the companies ahead of time, Forbes says. In a draft analysis posted Friday, the group concluded that, at a price of $30,000 per year, the drug cleared its threshold—handily—as measured by quality-adjusted life year (QALY) calculations. Generally, that threshold, per ICER, is $150,000 per QALY, and, after considering the cost of standard treatments, the quality-of-life and productivity improvements for patients, and some other variables, the group crunched out $97,600. Looking at severe patients as a discrete group, the analysis came to $75,100. And while $37,000 isn’t $30,000, Jefferies analysts expect the net price to Sanofi and Regeneron to be in the “low 30s,” and Bernstein’s Gal figures it will come in even lower, “in the ballpark of $24,000 to $26,000 per year.” And even at that price, Gal sees Dupixent bringing in $1.5 billion in atopic dermatitis, with a future asthma indication worth even more.
Wow. This is why Amgen reps are considered dumb as shit. Amgen doesn't own the patent for the ATOPIC DERMATITIS drug doofus.
“Amgen does have a patent covering the product, and we will defend our patent rights,” a company (Amgen) spokeswoman said via email. Amgen LAW will tear Regeneron and Sanofi apart, again.
Amgen owns a general patent for the targets. But unless you directly infringe on a specific sequence, it's non enforceable. You can enforce a patent of a target, otherwise, the TNF market would only have one product and Humira, Cimzia, etc would never be a competitor or cialis would not exist because of viagra.
Almost verbatim to what you posted on the REGN board...what's the WAC pricing on granddaddy Enbrel these days without any new data since 2006? And don't cite the new Peds data as being "new"...it's 11 years old
Enbrel for Rheum is $50.4k a year , derm even more with 2X weekly loading dose for 3 months. PsO is $60k a year so this is a steal. $37k wac is cheap. http://www.pressherald.com/2016/09/07/letter-to-the-editor-wheres-the-outrage-over-humira-enbrel-price-rises/
I posted nothing on the other board. I only go to the board of the company I work for. Stop stalking Amgen. Are you a disgruntled Regeneron or Sanofi rep?
New innovative med and one of its kind is 37k while Enbrel is old with many options at 60k Amgen is a greedy lil bitch!
